Immunocardiology
Carsten Tschöpe
![[Translate to englisch:]](/fileadmin/_processed_/e/0/csm_Portrait_Carsten_Tsch%C3%B6pe_f9d5e9ca17.webp "[Translate to englisch:]")
Inflammation is recognized as an important predictor for a worse outcome in heart failure. Underlying mechanisms of cardiac inflammation involving the innate and adaptive immune system, are incompletely understood. Based on endomyocardial biopsy analyses and immune profiles of well-characterized patient collectives, and experimental in vitro and in vivo models, we aim at gaining insights in the involvement of the immune system in heart failure and at finding potential biomarkers of heart failure. For the latter, particularly the use of hypothesis-free imaging mass spectrometry, covered by the integrated cardioproteomics group, is of importance. In addition, novel anti-inflammatory strategies are evaluated in experimental models of heart failure, which upon success, are translated into the clinic. On the other hand, working mechanisms of novel therapeutics used in the clinic are investigated in in vitro and in vivo settings. The impact of those therapeutical strategies on the cardiac proteomic signature is on its turn evaluated by cardioproteomics, highlighting the strong interactions among the clinical, experimental immunocardiology and the cardioprotemics group.
Aims
- Stratification of heart failure patients based on phenomapping
- Identification of biomarkers
- Identification of patient-specific therapy options (precision medicine)
- Clinical proof-of concept trials on anti-inflammatory or immunomodulatory interventions in patients with heart failure
Publications
Publications
Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence: providing evidence that patients with inflammatory cardiomyopathy and parvovirus B19 persistence without signs of systemic active infection may gain a similar long lasting and safe benefit from immunosuppressive treatment, as do virus-negative individuals.
Targeting CD20+ B lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: illustrating that CD20+ B-lymphocyte persistence can play a pathophysiologic role in a subset of inflammatory dilated cardiomopathy patients and highlighting the potential of targeting CD20+ B cells in patients with prominent CD20+ B-lymphocyte persistence.
Management of myocarditis-related cardiomyopathy in adults: summarizing recent advances in translational research that influence the utility of endomyocardial biopsy for the management of inflammatory cardiomyopathies and emerging therapies for myocarditis based on these mechanistic hypotheses.
Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy: adressing the need to stratify patients with dilated cardiomyopathy via omics-approaches (phenomics) and clinical parameters (phenomapping)
Team
Postdoctotal clinical scientist
Dr. Ahmed Elsanhoury, ahmed.elsanhoury@charite.de
Clinicians
Dr. Uwe Kühl, MD, Uwe.Kühl@charite.de
Dr. Frank Spillmann, MD, Frank.Spillmann@charite.de
Monika Willner (heart failure study nurse), monika.willner@charite.de
